SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Goldline Pharmaceutical Ltd (544759)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544759 NSE: Pharmaceuticals & Drugs | Small Cap | Goldline Pharmaceuti Share Price

₹42.96 0.00 (0.00%)

As on 04-Jun'26 16:59

Goldline Pharmaceutical Ltd (544759)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544759 NSE: Pharmaceuticals & Drugs | Small Cap | Goldline Pharmaceuti Share Price

₹42.96 0.00 (0.00%)

As on 04-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹41 Cr.
Current Price
₹43
52-Week Low / High
₹42 / 60
TTM EPS
₹3
TTM Sales
₹28.1 Cr.
Book Value per Share
₹21
P/E Ratio
14.55
Lower than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
2.05
Lower than its 5-year historical median
Price to Sales (P/S)
1.47
Lower than its 5-year historical median
EV/EBITDA
8.43
Lower than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
38.81%
Outperforms industry median
Return on Capital Employed (ROCE)
28.75%
Outperforms industry median
Return on Assets (ROA)
11.52%
Operating Profit Margin
21.9%
Net Profit Margin
10.1%
Gross Profit Margin
14.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
19.05%
Operating Profit Growth (1 Year)
-
40.93%
Net Profit Growth (1 Year)
-
56.35%
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
₹11 Cr.
Equity
₹9.6 Cr.
Face Value
₹10
All Time Low / High
₹41.76 / 60.00

Goldline Pharmaceutical stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Goldline Pharmaceutical Ltd a good quality company?
Goldline Pharmaceutical Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Goldline Pharmaceutical Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Goldline Pharmaceutical Ltd vs industry peers?
Goldline Pharmaceutical Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 6.81%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Goldline Pharmaceutical Ltd?
Promoters hold % of the Goldline Pharmaceutical Ltd, with % of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Goldline Pharmaceutical Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Goldline Pharmaceutical Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'23Mar'24Mar'25TTM
ROCE % 12.2%23.2%28.8%-
Value Creation
Index
-0.10.71.1-

Growth Parameters

Sales 19.923.628.128
Sales YoY Gr.-18.7%19.1%-
Adj EPS 0.72.74.23
YoY Gr.-297%57.9%-
BVPS (₹) 6.88.812.421
Adj Net
Profit
0.41.82.93
Cash Flow from Ops. 2.42.92.3-
Debt/CF from Ops. 4.53.84.8-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANANA19.1%
Adj EPS NANANA57.9%
BVPSNANANA41.1%
Share Price - - - -

Key Financial Parameters

Mar'23Mar'24Mar'25TTM
Return on
Equity %
6.826.731.817.7
Op. Profit
Mgn %
12.218.421.9NAN
Net Profit
Mgn %
27.810.310.1
Debt to
Equity
1.81.41.1-
Working Cap
Days
02752660
Cash Conv.
Cycle
02191920

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Sales19.8523.5728.06
Operating Expenses + 17.6419.2622
Manufacturing Costs0.330.360.32
Material Costs5.525.7410.51
Employee Cost 4.635.575.75
Other Costs 7.157.595.42
Operating Profit 2.214.306.06
Operating Profit Margin (%) 11.1%18.3%21.6%
Other Income + 000
Exceptional Items 000
Interest 1.631.611.95
Depreciation 0.180.160.25
Profit Before Tax 0.402.533.86
Tax 0.140.721.02
Profit After Tax 0.261.812.83
PAT Margin (%) 1.3%7.7%10.1%
Adjusted EPS (₹)0.42.64.1
Dividend Payout Ratio (%)0%0%0%

Valuation of Goldline Pharmaceuti - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 5.897.8710.35
Share Capital 3.814.118.71
Reserves 2.083.761.65
Debt +8.779.788.84
Long Term Debt3.814.053.19
Short Term Debt4.965.735.65
Minority Interest000
Trade Payables0.871.642.06
Others Liabilities 3.863.655.03
Total Liabilities 19.3922.9326.28

Fixed Assets

Net Fixed Assets +2.502.952.89
Gross Block2.923.523.71
Accumulated Depreciation0.420.570.82
CWIP 00.450
Investments 0.070.030.04
Inventories5.377.496.78
Trade Receivables8.639.6210.69
Cash Equivalents 0.050.791.24
Others Assets 2.771.604.64
Total Assets 19.3922.9326.28

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Cash Flow From Operating Activity + 2.392.922.32
PBT 0.402.533.86
Adjustment 21.822.07
Changes in Working Capital 0.03-1.23-2.69
Tax Paid -0.04-0.20-0.91
Cash Flow From Investing Activity + -1.03-1.110.16
Capex -1.01-1.110.17
Net Investments -0.030-0.01
Others 00-0
Cash Flow From Financing Activity + -1.44-1.08-2.03
Net Proceeds from Shares 00.450
Net Proceeds from Borrowing -2.200.24-0.86
Interest Paid -1.62-1.61-1.72
Dividend Paid -0.22-0.22-0.21
Others 2.600.060.76
Net Cash Flow -0.090.740.45

Financial Ratio

PARTICULARSMar'23Mar'24Mar'25
Ratios
ROE (%)6.2835.6238.81
ROCE (%)12.1723.1828.75
Asset Turnover Ratio1.021.111.14
PAT to CFO Conversion(x)9.191.610.82
Working Capital Days
Receivable Days158.70141.30132.20
Inventory Days98.8099.6092.80
Payable Days57.3079.9064.30

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Goldline Pharmaceutical Ltd FAQs

The current trading price of Goldline Pharmaceuti on 04-Jun-2026 16:59 is ₹42.96.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Goldline Pharmaceuti stood at ₹41.24 Cr

The latest P/E ratio of Goldline Pharmaceuti as of 03-Jun-2026 is 14.55.

The latest P/B ratio of Goldline Pharmaceuti as of 03-Jun-2026 is 2.05.

The 52-week high of Goldline Pharmaceuti is ₹60.00 and the 52-week low is ₹41.76.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Goldline Pharmaceuti is ₹28.06 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Goldline Pharmaceutical Ltd is a below average quality company.

The key valuation ratios of Goldline Pharmaceutical Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Goldline Pharmaceutical Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Goldline Pharmaceutical Ltd

Goldline Pharmaceutical was originally incorporated on August 2, 2004, as a private limited company in the name of ‘Goldline Pharmaceutical Private Limited’ under the provisions of the Companies Act, 1956 with the Registrar of Companies, Maharashtra at Mumbai. Subsequently pursuant to a special resolution passed by its Shareholders in the Extra-Ordinary General Meeting held on July 18, 2013, the company was converted from a private limited company into a public limited company and consequently, the name of the company was changed to ‘Goldline Pharmaceutical Limited’ and a fresh certificate of incorporation dated September 23, 2013 was issued by the Registrar of Companies, Maharashtra at Mumbai.

Goldline Pharmaceutical is engaged in the business of marketing pharmaceutical products under the brand name ‘Goldline’. The products sold under the ‘Goldline’ brand are categorized into five segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed by the company are not manufactured by the company. Instead, it enters into agreements with third-party manufacturers who produce these products for the company. The order for manufacturing to third party is based on market research and analysis. These manufacturers operate under specific contractual arrangements, ensuring that the products meet the requisite standards and specifications. Once the products are manufactured, it sells them under its brand name ‘Goldline’. 

Its customers primarily include distributors, who may further categorize as retailers and wholesalers. These distributors form the main channel through which its products reach the end-users. It maintains contractual and business arrangements with the manufacturers to ensure a consistent supply of products for marketing and sale under its brand name. It has established contractual arrangements, with manufacturers for the production of its pharmaceutical products and distributors for marketing and selling.

Business area of the company

Goldline Pharmaceutical is engaged in the business of marketing pharmaceutical products under the Goldline brand. Its products are divided into five categories: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Valiente. Its primary customers are distributors, who are further categorized as retailers and wholesalers. These distributors serve as the key channel through which its products reach the end-users.

Company's product categories

  • Goldline Pharma: This category includes 42 products designed to cater to specialties such as Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology.
  • Goldline Cardinal: This category comprises 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians.
  • Goldline Aayushman: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners.
  • Goldline In Life: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians.
  • Goldline Wellness: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy, aiming to enhance the quality of life while patients endure the challenges of the disease.

History and milestones

  • 2004: Incorporation of the company as a private company under the name ‘Goldline Pharmaceutical Private Limited.’ 
  • 2013: Conversion of the company from a private limited company to a public company and the new name of company as ‘Goldline Pharmaceutical Limited.’

Awards, accreditations and recognitions

  • 2014: In recognition of its immense participation in organising the 1st world congress of Coloproctology, it was awarded with a certificate of participation by the organisation secretaries of International Society of Coloproctologists.
  • 2015: In recognition of its immense participation in the 5th International CME in Gastroenterology & Hepatology, it was awarded with a certificate of participation by the Midas Medical Foundation & Research Institute, Nagpur.
  • 2018: In recognition of its immense participation in the Conference on Gastroenterology & Hepatology, it was awarded with a certificate of participation by the Midas Medical Foundation & Research Institute, Nagpur.
  • 2018: In recognition of its immense participation in the Trade Exhibition of Gastrocon, it was awarded with the Best Stall award by the Midas Medical Foundation & Research Institute, Nagpur.
  • 2019: In recognition of its immense participation in the 14th International Conference of Association of Minimal Access Surgeons of India, it was awarded with a Best Stall & Trade Partner Award by the organising committee of 14th International Conference of Association of Minimal Access Surgeons of India.
  • 2024: In recognition of its immense participation in organising the Midterm CME, it was awarded with a certificate of valuable contribution by the API Sambalpur City Branch, Deogarh in Association with the Association of Physicians of India.
  • 2025: In recognition of its immense participation for the contribution by way of sponsorship in organising the Midas Liver Meet, 2025, it was awarded with a certificate of participation by the organising committee of Midas Liver Meet 2025.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×